›2.↳ 1The solid form of claim 1, selected from a substantially amorphous form of compound 1 selected from form XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV,…d2+13

›3.↳ 2The solid form (XVII) of claim 2, characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 20.d3

›4.↳ 2The solid form (XVIII) of claim 2, characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 21.d3

›5.↳ 2The solid form (XIX) of claim 2, characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 22.d3

›6.↳ 2The solid form (XX) of claim 2, characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 23.d3

›7.↳ 2The solid form (XXI) of claim 2, characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 24.d3

›8.↳ 2The solid form (XXII) of claim 2, characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 25.d3

›9.↳ 2The solid form (XXIII) of claim 2, characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 26.d3

›10.↳ 2The solid form (XXIV) of claim 2, characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 27.d3

›11.↳ 2The solid form (XXV) of claim 2, characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 28.d3

›12.↳ 2The solid form (XXVI) of claim 2, characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 29.d3

›13.↳ 2The solid form claim 2, wherein the solid form is prepared by a spray dispersion process.d3

›14.↳ 2The solid form of claim 2, wherein the polymer is selected from hydroxypropyl methyl cellulose acetate succinate (HPMCAS), hydroxypropylmethyl cellulo…d3

›15.↳ 2A pharmaceutical composition comprising at least one solid form according to claim 2, or a pharmaceutically acceptable salt thereof, and a pharmaceuti…d3

›16.↳ 1The solid form of claim 1, selected from a solvate of form III, IV, V, VI, VII, IX, X, XI, XII, XIII, XIV or XV.d2+14

›19.↳ 16A solid form (form III) according to claim 16, characterized by an X-ray powder diffraction pattern comprising characteristic peaks at approximately 9…d3

›20.↳ 16A solid form (form IV) according to claim 16, characterized by an X-ray powder diffraction pattern comprising characteristic peaks at approximately 5.…d3

›21.↳ 16A solid form (form V) according to claim 16, characterized by an X-ray powder diffraction pattern comprising characteristic peaks at approximately 12.…d3

›22.↳ 16A solid form (form VI) according to claim 16, characterized by an X-ray powder diffraction pattern comprising characteristic peaks at approximately 7.…d3

›23.↳ 16A solid form (form VII) according to claim 16, characterized by an X-ray powder diffraction pattern comprising characteristic peaks at approximately 7…d3

›24.↳ 16A solid form (form IX) according to claim 16, characterized by an X-ray powder diffraction pattern comprising characteristic peaks at approximately 9.…d3

›25.↳ 16A solid form (form X) according to claim 16, characterized by an X-ray powder diffraction pattern comprising characteristic peaks at approximately 7.4…d3

›26.↳ 16A solid form (form XI) according to claim 16, characterized by an X-ray powder diffraction pattern comprising characteristic peaks at approximately 8.…d3

›27.↳ 16A solid form (form XII) according to claim 16, characterized by an X-ray powder diffraction pattern comprising characteristic peaks at approximately 7…d3

›28.↳ 16A solid form (form XIII) according to claim 16, characterized by an X-ray powder diffraction pattern comprising characteristic peaks at approximately …d3

›29.↳ 16A solid form (form XIV) according to claim 16, characterized by an X-ray powder diffraction pattern comprising characteristic peaks at approximately 5…d3

›30.↳ 16A solid form (form XV) according to claim 16, characterized by an X-ray powder diffraction pattern comprising characteristic peaks at approximately 12…d3

›31.↳ 16A solid form designated â€œpattern 6â€ according to claim 16, characterized in that it comprises signals in its X-ray powder diffraction curve at posi…d3

›37.↳ 16A pharmaceutical composition comprising at least one of the solid forms according to claim 16, together with pharmaceutically acceptable additives, ca…d3

›17.↳ 1The solid form of claim 1, selected from a polymorph of form VIII or XVI.d2+2

›18.↳ 1The solid form of claim 1, selected from the sulfuric acid-, hydrobromic acid- or hydrochloric acid salt of compound 1.d2+3

Classifications

7 codes

IPC · International Patent Classification

Section A — Human necessities

A01N43/42
A61K31/44

Section C — Chemistry; metallurgy

C07D498/02
C07D471/02
C07D491/02

USPC · US Patent Classification

514/300546/113

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

2.3 y

840 days filing → grant

Office actions

none on record

Responses

1 RCE

Interviews

examiner interview summaries

Examiner

Niloofar Rahmani

art unit 1625 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 765 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

2 priority documents

Priority

21 Feb 2011

earliest claimed

›Priority documents — 2

Type	Document	Date
provisional	US 61444866	21 Feb 2011
related publication	US 20140039002 A1	6 Feb 2014

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.